Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00005977
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/19/2013
Locations: St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
Conditions: Leukemia, Lymphoma
Register for Updates
Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
NCT00021359
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with dexamethasone may be an effective treatment for multiple myeloma. PURPOSE: Phase II trial to study the effectiveness of combining isotretinoin and dexamethasone in treating patients who have multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2013
Locations: Bon Secours-Holy Family Health System, Altoona, Pennsylvania +10 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
NCT00002471
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have acute B-lymphoblastic leukemia or recurrent non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
All
Trial Updated:
06/19/2013
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Leukemia, Lymphoma
Register for Updates
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
NCT00006345
Completed
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2013
Locations: Hahnemann University Hospital, Philadelphia, Pennsylvania +1 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Register for Updates
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
NCT00530270
Terminated
People with sickle cell disease (SCD) may develop acute chest syndrome (ACS), which is a common and serious lung condition that usually requires hospitalization. Dexamethasone is a medication that may decrease hospitalization time for people with ACS, but it may also bring about new sickle cell pain. This study will evaluate the effectiveness of a dexamethasone regimen that includes a gradual dose reduction at decreasing hospitalization and recovery time in people with SCD and ACS.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
03/29/2013
Locations: St. Christopher's Hospital, Philadelphia, Pennsylvania
Conditions: Anemia, Sickle Cell
Register for Updates
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
NCT01505088
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
03/28/2013
Locations: Scheie Eye Institute, Philadelphia, Pennsylvania +1 locations
Conditions: Anterior Uveitis
Register for Updates
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
NCT00002704
Completed
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
01/31/2013
Locations: St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
Conditions: Leukemia
Register for Updates
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
NCT00492284
Completed
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis \[within 2 hours\] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy \[within 2 hours\]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/31/2011
Locations: Not set, Philadelphia, Pennsylvania +1 locations
Conditions: Choroidal Neovascularization, Macular Degeneration
Register for Updates
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
NCT00694135
Completed
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
08/27/2010
Locations: Pennsylvania College of Optometry, Elkins Park, Pennsylvania +1 locations
Conditions: Uveitis, Anterior
Register for Updates
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania +2 locations
Conditions: Multiple Myeloma
Register for Updates